No FDA-Approved Inhaled or Parenteral ADHD Treatments Currently Exist
There are currently no FDA-approved inhaled or parenteral (intravenous, intramuscular, or subcutaneous) formulations for treating ADHD. All approved ADHD medications are administered via oral routes (tablets, capsules, liquids, chewable tablets, orally disintegrating tablets) or transdermally (skin patches) 1, 2.
Available Non-Oral Formulations
While parenteral and inhaled routes are not available, transdermal delivery is the only non-oral FDA-approved option:
- Methylphenidate transdermal patch – provides extended symptom control without oral administration 2, 3
- Clonidine transdermal patch – available for non-stimulant treatment 2
- Amphetamine transdermal patch – recently approved as the first transdermal amphetamine formulation 4
These patches offer advantages for patients who cannot swallow pills or prefer to avoid oral medications, while maintaining once-daily dosing and reducing stigma associated with in-school medication administration 5, 6.
Why This Matters Clinically
The absence of parenteral or inhaled formulations reflects the pharmacological reality that ADHD requires sustained, controlled catecholaminergic enhancement in the prefrontal cortex over 8-12 hours daily 7. Parenteral routes would create problematic pharmacokinetic profiles with rapid peaks and troughs, increasing abuse potential and adverse effects while providing poor symptom control throughout the school/work day 2.
Current FDA-Approved Routes Include:
Oral formulations (stimulants and non-stimulants):
- Immediate-release tablets/capsules (2-3 times daily)
- Extended-release tablets/capsules (once daily)
- Liquid suspensions (methylphenidate extended-release oral suspension) 8, 5
- Chewable tablets 8, 6
- Orally disintegrating tablets 8, 6
Transdermal formulations:
- Methylphenidate patch
- Clonidine patch
- Amphetamine patch 4
Clinical Pitfall to Avoid
Do not attempt off-label parenteral administration of oral ADHD medications. The controlled-release mechanisms in extended-release formulations are designed specifically for oral absorption and would be bypassed by parenteral routes, creating dangerous drug concentrations and eliminating the therapeutic benefit of sustained release 2.
If a patient cannot use oral or transdermal routes, atomoxetine or guanfacine remain oral-only options with "around-the-clock" effects that may reduce the frequency of administration concerns 2.